GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at Cambridge Health Institute’s BioProcessing ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting an educational webinar entitled “Large Scale, CHO Transient ...
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...
Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- ...
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc ...
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT), (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
Are low gene editing efficiency or gene expression levels preventing your research from advancing? Is your transfection method killing your cells? Are you struggling to reproduce your initial results ...
ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results